时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
Standard antiepileptic drugs (AEDs), including phenobarbital and potassium bromide, remain the cornerstone of treatment; however, they fail to achieve adequate seizure control in 20%–30% of patients (; ; ).；However, despite promising preclinical evidence, few clinical studies have evaluated the efficacy of curcuminoids in naturally occurring canine epilepsy.；Moreover, the molecular mechanisms underlying their potential therapeutic effects remain unknown.
方法
The study protocol was approved by the Mahidol University Institute Animal Care and Use Committee of the Faculty of Veterinary Science (Protocol No.；Eight client-owned dogs with PES were enrolled alongside five healthy adult dogs (aged 1–6 years; mixed breeds and purebreds; no history of neurological disease, seizures, or systemic illness) recruited from the same institution as a proteomic reference control group.；Multi-layered statistical filtering (ANOVA, FDR correction, and VIP scoring) was applied to minimize false discoveries in the high-dimensional dataset.；Validation in larger, prospectively powered cohorts is required.
核心结论
Clinical response (≥25% reduction in seizure frequency and/or ≥1 grade reduction in seizure severity) was observed in four dogs (50%) ().；Within responder group, three dogs (No. 1, 2, and 6) exhibited decreased seizure frequency, and one dog (No. 7) showed improved seizure symptoms with reduced clonic movements.；In the four non-responder dogs (No. 3,4, 5, and 8), seizure frequency and severity remained stable compared with baseline, with no significant changes being observed. ‖ 结论：These findings support the integration of curcuminoids into multimodal epilepsy management strategies in veterinary medicine, with potential translational implications for human epilepsy therapy.
局限
In this uncontrolled pilot study (n = 8), curcuminoid supplementation was safe, well tolerated, and yielded a clinical response rate of 50% in dogs with PES; however, the absence of a concurrent control group limits interpretation to preliminary evidence of an association rather than definitive evidence of efficacy.；The 50% clinical response rate observed in this preliminary is comparable to those reported for second-line AEDs in canine epilepsy ().；The finding that clinical improvement occurred in only 50% of dogs suggests potential heterogeneity in therapeutic response, which may be related to individual differences in curcuminoid bioavailability, genetic polymorphisms affecting drug metab
对本项目的价值
★☆☆☆☆ 干预证据决定参照标准效应量——任何抗衰干预的收益至少应对标该基线。设计 open-label。
全文来源
PMC JATS 全文（正文 48,523 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Curcuminoid supplementation alters proteomic profiles and clinical outcomes in canine primary epilepsy: A pilot study.
- 期刊与标识：Vet Anim Sci · PMID 42959793 · DOI 10.1016/j.vas.2026.100906
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。